+804.1%
AMKR vs MRNA
+554.4%
+249.7%
-65.9%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for all.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +4.4% | +5.4% | -0.9% | +4.2% |
| 7D | +8.3% | -1.1% | +9.4% | +8.3% |
| 30D | -6.8% | +126.1% | -132.9% | -15.6% |
| 3M | -31.9% | +190.0% | -222.0% | -40.9% |
| 6M | +18.4% | +157.2% | -138.9% | +4.2% |
| YTD | +31.7% | +388.2% | -356.5% | +6.9% |
| 1Y | +105.2% | +467.0% | -361.8% | +62.8% |
| 3Y | +147.7% | +36.1% | +111.7% | +120.1% |
| 5Y | +99.4% | -68.0% | +167.3% | +82.4% |
| All | +804.1% | +554.4% | +249.7% | +755.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over all: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
all analysis · Full analysis span regression · 6 months rolling